Review of current staging systems for hepatocellular carcinoma
Hobyung Chung(Kindai University), Toyokazu Fukunaga, Shunsuke Takahashi(Kanagawa Dental University), Kazuomi Ueshima(Kindai University), Tatsuo Inoue, Yasunori Minami(Kindai University), Satoru Hagiwara(Kindai University Hospital), Yasuhiro Sakaguchi(Jikei University Kashiwa hospital), Masatoshi Kudo(Kindai University)
Cited by 8
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Development of a Prokaryotic Universal Primer for Simultaneous Analysis of Bacteria and Archaea Using Next-Generation Sequencing
|PLoS ONE|2014|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k